We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
- Authors
Fidias, Panos M; Dakhil, Shaker R; Lyss, Alan P; Loesch, David M; Waterhouse, David M; Bromund, Jane L; Chen, Ruqin; Hristova-Kazmierski, Maria; Treat, Joseph; Obasaju, Coleman K; Marciniak, Martin; Gill, John; Schiller, Joan H
- Abstract
Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced non-small-cell lung cancer (NSCLC). For patients without progression, timing of second-line chemotherapy for optimum clinical benefit remains uncertain. This phase III, randomized trial assessed the efficacy and safety of docetaxel administered either immediately after GC or at disease progression.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 4, p591
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.17.1405